Why the study?
Real-world experience regarding the treatment and outcomes of female patients with a history of breast cancer presenting with STEMI is lacking.
Does a history of breast cancer affect the utilization of therapies and in-hospital outcomes in females admitted for STEMI?
Does a history of breast cancer affect the utilization of therapies and in-hospital outcomes in females admitted for STEMI?
Females with a history of breast cancer presenting with STEMI experience higher in-hospital mortality and cardiogenic shock, alongside underutilization of revascularization and mechanical circulatory support.
Real-world STEMI data in breast cancer survivors remain sparse; this analysis leaves open questions on optimal therapies and outcomes.
Background Real world experience of treatment of female patient with history of breast cancer suffering from STEMI is lacking Purpose To study the trends, utilization of therapies and outcomes of STEMI in females with history of breast cancer from a large, national, multicenter US database. Methods We analyzed Nationwide Inpatient Sample from years 2007 to 2014 to identify all females with primary discharge diagnosis of STEMI and secondary diagnosis of breast cancer. We then analyzed the use of various therapies and outcomes. Results Of 476,462 females with STEMI hospitalizations, 17, 357 (3.65%) had history of breast cancer. In this patient cohort the mean age was 75.81±11.82 years and 85% were Caucasians, hypertension, diabetes mellitus, chronic kidney disease and peripheral vascular disease was present in 29.5%, 70.3%, 12.4% and 8.3% respectively. 50% of the patients underwent percutaneous coronary intervention (PCI) and 3% underwent coronary artery bypass surgery (CABG). Intra-aortic balloon pump was used in 5.2% and percutaneous LVAD (PLVAD) in 0.5%. 15.3% patients developed cardiogenic shock (CS) and 6.2% had ventricular fibrillation/cardiac arrest (Vfib/CA). The in-hospital mortality was 12.3%. Comparison of female patients for STEMI with and without history of breast cancer Group Patients No Age (mean) PCI CABG IABP PLVAD CS Vfib/CA Mortality STEMI / Breast cancer − 495,105 69±14 54% 4.5% 6.5% 3% 9.42% 8.1% 9.7% STEMI / Breast cancer + 17,357 75.8±11.8* 50%* 3%* 5.2%* 0.5%* 15.3%* 6.2%* 12.3%* *P<0.05. Conclusion The STEMI/breast cancer cohort is significantly older with underutilization of PCI, CABG, and mechanical circulatory support. This population exhibits higher mortality rates. Acknowledgement/Funding None
No takes yet. Share an insight, caveat, or question.
Mastoris et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: